The elmiric acids: biologically active anandamide analogs.

elmiric Acids:具有生物活性的 anandamide 类似物。

基本信息

项目摘要

As chemical entities, lipoamino acids have been known for some time. However, more recently their occurrence and importance in mammalian species has been discovered. They appear to have close relationships with the endocannabinoids not only structurally but also in terms of biological actions. The latter include analgesia, anti-inflammatory effects, inhibition of cell proliferation and calcium ion mobilization. To date about 40 naturally occurring members of this family have been identified and, additionally, several synthetic analogs have been prepared and studied. To facilitate their identity, a nomenclature system has been suggested based on the name elmiric acid (EMA). The prototypic example, N-arachidonoyl glycine does not bind to CBI, however it does inhibit the glycine transporter GLYT2a and also appears to be a ligand for the orphan G-protein-coupled receptor GPRI8. It may also have a role in regulating tissue levels of anandamide by virtue of its inhibitory effect on FAAH the enzyme that mediates inactivation of anandamide. Its concentration in rat brain is several times higher than anandamide supporting its possible role as a physiological mediator. Future studies should be aimed at elucidating the actions of all of the members of this interesting family of molecules and gaining further insight into possible mechanisms of action. A promising use for these compounds would be as narcotic replacement agents.
作为化学实体,脂肪氨基酸已经闻名了一段时间。但是,更多 最近发现它们在哺乳动物物种中的发生和重要性。他们 似乎与内源性大麻素有着密切的关系 在生物行为方面。后者包括镇痛,抗炎作用, 抑制细胞增殖和钙离子动员。迄今为止大约40天自然 已经确定了这个家庭的成员,此外还有几个合成 已经准备好模拟并研究了类似物。为了促进其身份,术语系统 已经根据名称Elmiric Acid(EMA)提出了建议。原型示例N-芳基烯烯甘氨酸不与CBI结合,但是它确实抑制了甘氨酸转运蛋白 Glyt2a,似乎也是孤儿G蛋白偶联受体GPRI8的配体。 它也可能在调节组织水平的武anandamide抑制作用中起作用 对法族的影响,介导anandamide的失活的酶。它的集中度 老鼠大脑比Anandamide高出几倍,支持其作为一个可能的作用 生理调解人。未来的研究应旨在阐明所有的行动 这个有趣的分子家族的成员,并进一步了解可能 作用机理。这些化合物的有希望的用途将是麻醉品 替代剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUMNER HOWARD BURSTEIN其他文献

SUMNER HOWARD BURSTEIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUMNER HOWARD BURSTEIN', 18)}}的其他基金

The elmiric acids: biologically active anandamide analogs.
elmiric Acids:具有生物活性的 anandamide 类似物。
  • 批准号:
    7727687
  • 财政年份:
    2009
  • 资助金额:
    $ 32.43万
  • 项目类别:
Endocannabinoid Analogs as Anti-inflammatory Agents
作为抗炎剂的内源性大麻素类似物
  • 批准号:
    7106374
  • 财政年份:
    2004
  • 资助金额:
    $ 32.43万
  • 项目类别:
Endocannabinoid Analogs as Anti-inflammatory Agents
作为抗炎剂的内源性大麻素类似物
  • 批准号:
    6951593
  • 财政年份:
    2004
  • 资助金额:
    $ 32.43万
  • 项目类别:
Endocannabinoid Analogs as Anti-inflammatory Agents
作为抗炎剂的内源性大麻素类似物
  • 批准号:
    6749403
  • 财政年份:
    2004
  • 资助金额:
    $ 32.43万
  • 项目类别:
Endocannabinoid Analogs as Anti-inflammatory Agents
作为抗炎剂的内源性大麻素类似物
  • 批准号:
    7678732
  • 财政年份:
    2004
  • 资助金额:
    $ 32.43万
  • 项目类别:
NON PSYCHOACTIVE CANNABINOIDS WITH THERAPEUTIC POTENTIAL
具有治疗潜力的非精神活性大麻素
  • 批准号:
    6175550
  • 财政年份:
    1999
  • 资助金额:
    $ 32.43万
  • 项目类别:
NON PSYCHOACTIVE CANNABINOIDS WITH THERAPEUTIC POTENTIAL
具有治疗潜力的非精神活性大麻素
  • 批准号:
    2902241
  • 财政年份:
    1999
  • 资助金额:
    $ 32.43万
  • 项目类别:
NON PSYCHOACTIVE CANNABINOIDS WITH THERAPEUTIC POTENTIAL
具有治疗潜力的非精神活性大麻素
  • 批准号:
    6378830
  • 财政年份:
    1999
  • 资助金额:
    $ 32.43万
  • 项目类别:
NON PSYCHOACTIVE CANNABINOIDS WITH THERAPEUTIC POTENTIAL
具有治疗潜力的非精神活性大麻素
  • 批准号:
    6515659
  • 财政年份:
    1999
  • 资助金额:
    $ 32.43万
  • 项目类别:
BIOSYNTHESIS OF ANANDAMIDE--A NOVEL EICOSANOID
新型二十烷酸阿南达胺的生物合成
  • 批准号:
    2122673
  • 财政年份:
    1995
  • 资助金额:
    $ 32.43万
  • 项目类别:

相似海外基金

Kappa Opioid Receptor in Paraventricular Nucleus of Thalamus
丘脑室旁核中的 Kappa 阿片受体
  • 批准号:
    10659960
  • 财政年份:
    2023
  • 资助金额:
    $ 32.43万
  • 项目类别:
Mechanism and Countermeasure of Fentanyl-Induced Sudden Death
芬太尼致猝死的机制及对策
  • 批准号:
    10586701
  • 财政年份:
    2023
  • 资助金额:
    $ 32.43万
  • 项目类别:
Targeting visceral pain through intestinal neuropod cell GUCY2C signaling
通过肠道神经足细胞 GUCY2C 信号传导治疗内脏疼痛
  • 批准号:
    10837293
  • 财政年份:
    2023
  • 资助金额:
    $ 32.43万
  • 项目类别:
Green Light Therapy for Chronic Pain
绿光疗法治疗慢性疼痛
  • 批准号:
    9925184
  • 财政年份:
    2018
  • 资助金额:
    $ 32.43万
  • 项目类别:
Green Light Therapy for Chronic Pain
绿光疗法治疗慢性疼痛
  • 批准号:
    10400839
  • 财政年份:
    2018
  • 资助金额:
    $ 32.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了